Sunshine Biopharma Inc. 8-K

What Happened
Sunshine Biopharma Inc. (SBFM) announced its financial results for the year ended December 31, 2025 via a press release issued April 6, 2026, and filed a Form 8-K on April 9, 2026 to report those results under Item 2.02 (Results of Operations and Financial Condition). The press release is included with the filing as Exhibit 99.1.

Key Details

• Press release announcing 2025 results issued April 6, 2026.
• Form 8-K filed April 9, 2026, reporting results for the year ended December 31, 2025 (Item 2.02).
• Press release attached as Exhibit 99.1 to the 8-K; the filing also includes the Inline XBRL cover page.
• The 8-K provides notice of the results; investors should review Exhibit 99.1 for the full financial figures (revenue, net income, cash position) and management commentary.

Why It Matters
This 8-K signals that Sunshine Biopharma has disclosed its annual earnings and financial condition to investors. Year‑end results can affect valuation, analyst estimates, and investor expectations for revenue, profitability, cash runway, and near‑term plans. Retail investors should read the attached press release and the company’s subsequent SEC filings for the specific numbers and any management discussion or guidance.